Daily Brief United States: IShares Bitcoin Trust ETF, Honeywell International, Microsoft Corp, Bitcoin, Unum Group, Mira Pharmaceuticals , MetaVia, Emerald Holding , Ryan Specialty Holdings and more

• Realize Volatility is a cause, not an effect, and can lead to inaction
• Options on iBit, the Bitcoin ETF, are becoming a critical industry risk management tool
• IBIT options have seen stunning volumes and substantial open interest, leading to price discovery and a growing liquidity ecosystem

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.

• Honeywell International has recently become the center of investor attention following mounting pressure from activist investor Elliott Investment Management.
• With a massive $5 billion stake, Elliott has called for the separation of Honeywell’s aerospace business, pushing the industrial giant toward a portfolio realignment.
• Honeywell’s board announced that it is actively considering a potential aerospace spin-off, signaling a possible strategic transformation.

• Microsoft’s aggressive acquisition of nearly half a million Nvidia AI chips underscore the tech giant’s all-in commitment to artificial intelligence (AI).
• As AI reshapes industries, Microsoft has found itself playing catch-up against Google, Amazon, and Meta, all of whom have already developed custom AI chips.
• By investing heavily in Nvidia’s cutting-edge Hopper GPUs, Microsoft has managed to build out a formidable AI infrastructure but at a significant cost.

• I have mentioned this before, and I am happy to emphasize it once again: the supply of block space far exceeds demand.
• There is simply not enough activity, use cases, or applications to fill the available block space across all smart contract-capable blockchains.
• This imbalance is why I firmly believe that adoption and network activity are the most critical factors for any blockchain seeking to compete with Ethereum, Solana, or the few other networks that have gained significant traction.

• Unum Group has reported its third-quarter 2024 financial performance, accentuating a strong overall operational landscape with both prospects and challenges.
• On the positive side, adjusted earnings per share (EPS) were reported at $2.13, contributing to over $1 billion in statutory earnings year-to-date.
• This performance aligns with Unum Group’s objective of achieving EPS growth of 10% to 15% for the full year, surpassing initial estimates.

• Bitcoin, Ethereum, and Solana are all incorporating ZK technology in different ways for various purposes.
• Muhammad discusses the development of FHE and its application in creating private ERC20 tokens for enhanced privacy and security.
• Each ecosystem (Bitcoin, Ethereum, Solana) is using ZK technology differently to address specific challenges and enhance functionality for users.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.

• MIRA Pharmaceuticals(MIRA) Company Sponsored Research Report

• On December 18, 2024, MetaVia announced positive topline results from the Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH).
• The results showed a statistically significant decrease in alanine aminotransferase (ALT) levels, the trials primary outcome, for DA-1241 100 mg at weeks 4 and 8 and statistically significant results were also seen in controlled attenuation parameter (CAP) and hemoglobin A1c.
• DA-1241 was well tolerated with only 35% of patients on the 100 mg dose reporting a treatment related adverse event (TEAE) compared to 28% on placebo.

• Investors pushed up EEX due to bullish trading recommendations by Nomura
• Nomura may have miscalculated net buying needed, leading to stock correction
• Correction in EEX is now seen as overdone, presenting undervalued opportunity for short-term trades and long-term investments

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

• Ryan Specialty Holdings reported a solid performance in its third quarter of 2024, with key financial metrics indicating overall positive momentum despite certain market challenges.
• The company achieved a 20.5% increase in total revenue, driven by a combination of 11.8% organic revenue growth and contributions from mergers and acquisitions.
• The quarter’s adjusted EBITDAC rose by 29.4% to $190 million, with margins expanding by 220 basis points to 31.5%.